The Protein Biomarker 
Company

Specializing in Oncology Protein Biomarkers

 

A new, revolutionary way to quickly evaluate the efficacy of various treatments on over 80% of cancers

SERVICES

AND PRODUCTS

 

Highly innovative, unique and rapid diagnostic solutions for efficient drug development and personalized treatment.

Services:  Molecular Decisions provides boutique CRO services to pharmaceutical companies, helping them do faster and more confident drug development and clinical trials. The company analyzes clinical or analytical samples using nanoimmunoassays that precisely measure specific protein isoform drug targets, enabling sound, immediate decisions related to drug efficacy.

Testing. We adapt our clients’ assays to the Molecular Decisions platform and then test their samples using those assays.
This process yields both precise results and, if desired, additional insights into the relevant protein signature. 
The strong expertise of the Molecular Decisions lab reduces both the risk and resources needed by client. 

Assay development.  We assist clients in developing or refining assays.  

Molecular Decisions’ expertise complements the internal resources of clients to help develop their assays or to expand their assay candidates to include specific protein isoforms.

The company has validated tests for a number of cancer targets.    We have developed independent protein assays for kidney, lung, ovarian, breast, endometrial, lymphoma, leukemia and myelodysplasia.

Products:  Molecular Decisions is developing and co-developing diagnostics and reagents with a focus on cancer.  The company is poised to develop hundreds of novel assays and is able to work on non-cancer assays.

OUR VISION

A new generation of therapeutics and diagnostics that dramatically reduce patient suffering.

Although measuring DNA, RNA or proteins has the appeal of being operationally straightforward, it is often inadequate since specific protein modifications are frequently the relevant indicators of a disease state or therapeutic response of interest.   Molecular Decisions, brings sophisticated proteomics to bear to enable a new generation of more effective therapeutics and diagnostics.

Molecular Decisions delivers on the promise of proteomics.

Molecular Decisions provides services to pharmaceutical companies, helping them do faster and more confident drug development and clinical trials. The company analyzes clinical or analytical samples using nanoimmunoassays that precisely measure specific protein isoform drug targets, enabling sound, immediate decisions related to drug efficacy.

 
 

WHO WE ARE

Dean Felsher,M.D. Ph.D.
Chairman, Director and Founder
Alice Fan, M.D.
Director and Founder
Jonathan Dávila, Ph.D
CEO and President
Rich Brenner
Director
Olga Petrauskene, Ph.D.
Director

CONTACT

MOLECULARDECISIONS

OUR ADDRESS

For any general inquiries, please fill in the following contact form:

 

© 2019 by Molecular Decisions

  • Facebook Social Icon
  • LinkedIn Social Icon